Business
Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy
Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditionsMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditions","length":173,"tagName":"p"},{"type":"text","content":"MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech Ltd., an Israeli-based medical technology company focused on automated kidney function monitoring. The transaction is expected to close following the satisfaction of customary closing conditions.","length":523,"tagName":"p"},{"type":"text","content":"The Rendiatech securities purchase agreement represents a strategic expansion of Nuwellis’ portfolio beyond therapeutic fluid management into real-time renal diagnostics, reinforcing the company’s long-term vision to commercialize differentiated cardiorenal offerings that support earlier detection of kidney stress and more informed clinical decision-making in high-acuity care settings.","length":388,"tagName":"p"},{"type":"text","content":"Rendiatech’s Clarity™ system is designed to provide automated, continuous renal monitoring through precise urine-output measurement, replacing manual collection and intermittent readings. Upon closing, Nuwellis expects that the addition of this technology will establish a foundation for future expansion into advanced urine-based analytics and broader kidney function assessment.","length":380,"tagName":"p"},{"type":"text","content":"“This agreement represents an important step in advancing our cardiorenal strategy,” said John Erb, Chief Executive Officer of Nuwellis. “By entering into this tran...